News

Dr. Reddy’s Laboratories Ltd. will hold a board meeting on October 23, 2026, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ending September 30, 2026, and the trading window for dealing in securities of the company will be closed from September 24, 2026, to October 25, 2026, inclusive.

Dr. Reddy’s Laboratories Ltd. announced the allotment of 375 equity shares of Re. 1/- each to eligible employees on September 10, 2026, following the exercise of stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007, resulting in a total issued share capital of Rs. 83,46,81,285 /- and 83,46,80,285 equity shares.

Dr. Reddy’s Laboratories Ltd. announced the allotment of 4,110 equity shares of Re. 1/- each to eligible employees on August 26, 2026, pursuant to the exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002, resulting in a total issued share capital of Rs. 83,46,80,910 /- and a total issued shares of 83,46,80,910.

Dr. Reddy`s Laboratories announced that the U.S. Food and Drug Administration (FDA) has approved its rituximab biosimilar, a biosimilar to Rituxan� (rituximab), for the U.S. market. The approval further strengthens Dr. Reddy`s growing global biosimilars portfolio and advances its biosimilars business in the United States. The product was developed, manufactured and submitted for approval by Dr. Reddy`s Laboratories. The approval follows the successful recent Pre-License Inspection (PLI) conducted by the U.S. FDA at the Company`s biologics manufacturing facility in Bachupally, Hyderabad, and reflects the company`s capabilities in bringing complex biologic medicines to highly regulated markets and its long-standing commitment to biosimilars. Under a commercialization agreement, Fresenius Kabi holds the exclusive rights to commercialize the product in the United States, one of the world`s most important pharmaceutical markets.

Net profit of Dr Reddy`s Laboratories declined 68.67% to Rs 444.30 crore in the quarter ended June 2026 as against Rs 1418.10 crore during the previous quarter ended June 2025. Sales declined 5.56% to Rs 8070.50 crore in the quarter ended June 2026 as against Rs 8545.20 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales8070.508545.20 -6 OPM %10.6525.44 - PBDT1089.902381.10 -54 PBT553.301905.00 -71 NP444.301418.10 -69 Powered by Capital Market - Live News